Health System Costs of Treating Latent Tuberculosis Infection With Four Months of Rifampin Versus Nine Months of Isoniazid in Different Settings
Mayara Lisboa Bastos(McGill University Health Centre), Dick Menzies(McGill University Health Centre), Richard Long, Jonathon R. Campbell(McGill University Health Centre), Mênonli Adjobimey(McGill University Health Centre), Joseph Obeng Baah(Komfo Anokye Teaching Hospital), Hamdan Al‐Jahdali(King Saud University), Olivia Oxlade, Anete Trajman(Universidade Federal do Rio de Janeiro), Rovina Ruslami(McGill University Health Centre), Brett G. Toelle(Woolcock Institute of Medical Research), Kevin Elwood(University of British Columbia), Lika Apriani(Padjadjaran University), Hee Jin Kim(Korea National Tuberculosis Association), Vernon Hoeppner(McGill University Health Centre), Andrea Benedetti(Montreal Heart Institute), Kevin Schwartzman(McGill University Health Centre)
Cited by 31
Related Papers
Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis
|BMJ|2020|920
Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis
|The Lancet|2018|639
Role of Transforming Growth Factor–β in Airway Remodeling in Asthma
|American Journal of Respiratory Cell and Molecular Biology|2010|420
Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults
|New England Journal of Medicine|2018|392
Criteria and definitions for the radiological and clinical diagnosis of bronchiectasis in adults for use in clinical trials: international consensus recommendations
|The Lancet Respiratory Medicine|2021|297